Dose–response relationship of lansoprazole to gastric acid antisecretory effects
Background: Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro‐oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 1998-04, Vol.12 (4), p.321-327 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 327 |
|---|---|
| container_issue | 4 |
| container_start_page | 321 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 12 |
| creator | BLUM, R. A HUNT, R. H KIDD, S. L SHI, H JENNINGS, D. E GRESKI-ROSE, P. A |
| description | Background:
Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro‐oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent upon the degree and duration of acid suppression and the length of treatment.
Objective:
To evaluate the extent and duration of gastric acid suppression of several lansoprazole regimens, administered for 5 consecutive days in 32 healthy adult male subjects.
Methods:
Intragastric 24‐h pH monitoring was performed in 32 healthy subjects in a randomized, double‐blind, four‐way crossover study. Sixteen subjects (Group 1) received lansoprazole 30 mg o.d. (once daily), 15 mg b.d. (twice daily), 30 mg b.d. and 30 mg t.d.s. (three times a day) for 5 days; and 16 subjects (Group 2) received lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. for 5 days.
Results:
Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 15 mg b.d., 30 mg b.d. and 30 mg t.d.s. were 4.47, 4.57, 5.07 and 5.63, respectively. Multiple‐dose regimens of lansoprazole 30 mg b.d. and t.d.s. produced greater acid suppression compared to lansoprazole 30 mg o.d. and 15 mg b.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 15 mg b.d. Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. were 4.13, 4.45, 5.19 and 5.13, respectively. Multiple‐dose regimens of lansoprazole 60 mg b.d. and t.d.s. produced significantly greater acid suppression compared to lansoprazole 30 mg o.d. and 60 mg o.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 60 mg o.d. Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s. produced significantly greater percentage time above pH 3, 4, 5 and 6 than did lansoprazole 30 mg o.d. Post‐regimen serum gastrin values increased by 50–130% from pre‐study mean values but remained within normal range and returned to pre‐study values 7–14 days post‐dosing.
Conclusions:
Multiple‐dose regimens of lansoprazole (≥30 mg b.d. for 5 days) produce significantly increased intragastric pH and significantly longer duration of increased intragastric pH than does lansoprazole 30 mg administered once daily. |
| doi_str_mv | 10.1046/j.1365-2036.1998.00306.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80047594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80047594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4426-6a42359542d018903bc1ae5c155e13581618c06d99636dc8737d629ee1e488563</originalsourceid><addsrcrecordid>eNqNkM9u1DAQhy0EKtvCIyD5gLgljO3YsSUuVYGCVAmEytlynQl4lV0HT1btcuIdeEOehIRd7ZnTjPT75o8-xriAWkBjXq9roYyuJChTC-dsDaDA1A-P2OoUPGYrkMZV0gr1lJ0TrQHAtCDP2JkzDloJK_blbSb88-t3QRrzlpAXHMKU5vZ7Gnnu-RC2lMcSfuYB-ZT5t0BTSZGHmDoetlMijAWnXPYc-x7jRM_Ykz4MhM-P9YJ9ff_u9upDdfPp-uPV5U0Vm0aayoRGKu10IzsQ1oG6iyKgjkJrFEpbYYSNYDrnjDJdtK1qOyMdosDGWm3UBXt12DuW_GOHNPlNoojD_DHmHXkL0LTaNTNoD2Asmahg78eSNqHsvQC_6PRrv1jzizW_6PT_dPqHefTF8cbuboPdafDob85fHvNAMQx9CduY6IRJKU3rFuzNAbtPA-7_-7y__Hw7N-ovSOuQmA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80047594</pqid></control><display><type>article</type><title>Dose–response relationship of lansoprazole to gastric acid antisecretory effects</title><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>BLUM, R. A ; HUNT, R. H ; KIDD, S. L ; SHI, H ; JENNINGS, D. E ; GRESKI-ROSE, P. A</creator><creatorcontrib>BLUM, R. A ; HUNT, R. H ; KIDD, S. L ; SHI, H ; JENNINGS, D. E ; GRESKI-ROSE, P. A</creatorcontrib><description>Background:
Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro‐oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent upon the degree and duration of acid suppression and the length of treatment.
Objective:
To evaluate the extent and duration of gastric acid suppression of several lansoprazole regimens, administered for 5 consecutive days in 32 healthy adult male subjects.
Methods:
Intragastric 24‐h pH monitoring was performed in 32 healthy subjects in a randomized, double‐blind, four‐way crossover study. Sixteen subjects (Group 1) received lansoprazole 30 mg o.d. (once daily), 15 mg b.d. (twice daily), 30 mg b.d. and 30 mg t.d.s. (three times a day) for 5 days; and 16 subjects (Group 2) received lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. for 5 days.
Results:
Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 15 mg b.d., 30 mg b.d. and 30 mg t.d.s. were 4.47, 4.57, 5.07 and 5.63, respectively. Multiple‐dose regimens of lansoprazole 30 mg b.d. and t.d.s. produced greater acid suppression compared to lansoprazole 30 mg o.d. and 15 mg b.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 15 mg b.d. Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. were 4.13, 4.45, 5.19 and 5.13, respectively. Multiple‐dose regimens of lansoprazole 60 mg b.d. and t.d.s. produced significantly greater acid suppression compared to lansoprazole 30 mg o.d. and 60 mg o.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 60 mg o.d. Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s. produced significantly greater percentage time above pH 3, 4, 5 and 6 than did lansoprazole 30 mg o.d. Post‐regimen serum gastrin values increased by 50–130% from pre‐study mean values but remained within normal range and returned to pre‐study values 7–14 days post‐dosing.
Conclusions:
Multiple‐dose regimens of lansoprazole (≥30 mg b.d. for 5 days) produce significantly increased intragastric pH and significantly longer duration of increased intragastric pH than does lansoprazole 30 mg administered once daily.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.1998.00306.x</identifier><identifier>PMID: 9690720</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Administration, Oral ; Adult ; Anti-Ulcer Agents - administration & dosage ; Anti-Ulcer Agents - pharmacology ; Anti-Ulcer Agents - therapeutic use ; Biological and medical sciences ; Cross-Over Studies ; Digestive system ; Dose-Response Relationship, Drug ; Double-Blind Method ; Gastric Acid - metabolism ; Gastroesophageal Reflux - drug therapy ; Humans ; Lansoprazole ; Male ; Medical sciences ; Omeprazole - administration & dosage ; Omeprazole - analogs & derivatives ; Omeprazole - pharmacology ; Omeprazole - therapeutic use ; Peptic Ulcer - drug therapy ; Pharmacology. Drug treatments</subject><ispartof>Alimentary pharmacology & therapeutics, 1998-04, Vol.12 (4), p.321-327</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4426-6a42359542d018903bc1ae5c155e13581618c06d99636dc8737d629ee1e488563</citedby><cites>FETCH-LOGICAL-c4426-6a42359542d018903bc1ae5c155e13581618c06d99636dc8737d629ee1e488563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2036.1998.00306.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2036.1998.00306.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2226790$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9690720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BLUM, R. A</creatorcontrib><creatorcontrib>HUNT, R. H</creatorcontrib><creatorcontrib>KIDD, S. L</creatorcontrib><creatorcontrib>SHI, H</creatorcontrib><creatorcontrib>JENNINGS, D. E</creatorcontrib><creatorcontrib>GRESKI-ROSE, P. A</creatorcontrib><title>Dose–response relationship of lansoprazole to gastric acid antisecretory effects</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Background:
Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro‐oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent upon the degree and duration of acid suppression and the length of treatment.
Objective:
To evaluate the extent and duration of gastric acid suppression of several lansoprazole regimens, administered for 5 consecutive days in 32 healthy adult male subjects.
Methods:
Intragastric 24‐h pH monitoring was performed in 32 healthy subjects in a randomized, double‐blind, four‐way crossover study. Sixteen subjects (Group 1) received lansoprazole 30 mg o.d. (once daily), 15 mg b.d. (twice daily), 30 mg b.d. and 30 mg t.d.s. (three times a day) for 5 days; and 16 subjects (Group 2) received lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. for 5 days.
Results:
Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 15 mg b.d., 30 mg b.d. and 30 mg t.d.s. were 4.47, 4.57, 5.07 and 5.63, respectively. Multiple‐dose regimens of lansoprazole 30 mg b.d. and t.d.s. produced greater acid suppression compared to lansoprazole 30 mg o.d. and 15 mg b.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 15 mg b.d. Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. were 4.13, 4.45, 5.19 and 5.13, respectively. Multiple‐dose regimens of lansoprazole 60 mg b.d. and t.d.s. produced significantly greater acid suppression compared to lansoprazole 30 mg o.d. and 60 mg o.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 60 mg o.d. Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s. produced significantly greater percentage time above pH 3, 4, 5 and 6 than did lansoprazole 30 mg o.d. Post‐regimen serum gastrin values increased by 50–130% from pre‐study mean values but remained within normal range and returned to pre‐study values 7–14 days post‐dosing.
Conclusions:
Multiple‐dose regimens of lansoprazole (≥30 mg b.d. for 5 days) produce significantly increased intragastric pH and significantly longer duration of increased intragastric pH than does lansoprazole 30 mg administered once daily.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Anti-Ulcer Agents - pharmacology</subject><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cross-Over Studies</subject><subject>Digestive system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Gastric Acid - metabolism</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Omeprazole - administration & dosage</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Omeprazole - pharmacology</subject><subject>Omeprazole - therapeutic use</subject><subject>Peptic Ulcer - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM9u1DAQhy0EKtvCIyD5gLgljO3YsSUuVYGCVAmEytlynQl4lV0HT1btcuIdeEOehIRd7ZnTjPT75o8-xriAWkBjXq9roYyuJChTC-dsDaDA1A-P2OoUPGYrkMZV0gr1lJ0TrQHAtCDP2JkzDloJK_blbSb88-t3QRrzlpAXHMKU5vZ7Gnnu-RC2lMcSfuYB-ZT5t0BTSZGHmDoetlMijAWnXPYc-x7jRM_Ykz4MhM-P9YJ9ff_u9upDdfPp-uPV5U0Vm0aayoRGKu10IzsQ1oG6iyKgjkJrFEpbYYSNYDrnjDJdtK1qOyMdosDGWm3UBXt12DuW_GOHNPlNoojD_DHmHXkL0LTaNTNoD2Asmahg78eSNqHsvQC_6PRrv1jzizW_6PT_dPqHefTF8cbuboPdafDob85fHvNAMQx9CduY6IRJKU3rFuzNAbtPA-7_-7y__Hw7N-ovSOuQmA</recordid><startdate>199804</startdate><enddate>199804</enddate><creator>BLUM, R. A</creator><creator>HUNT, R. H</creator><creator>KIDD, S. L</creator><creator>SHI, H</creator><creator>JENNINGS, D. E</creator><creator>GRESKI-ROSE, P. A</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199804</creationdate><title>Dose–response relationship of lansoprazole to gastric acid antisecretory effects</title><author>BLUM, R. A ; HUNT, R. H ; KIDD, S. L ; SHI, H ; JENNINGS, D. E ; GRESKI-ROSE, P. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4426-6a42359542d018903bc1ae5c155e13581618c06d99636dc8737d629ee1e488563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Anti-Ulcer Agents - pharmacology</topic><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cross-Over Studies</topic><topic>Digestive system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Gastric Acid - metabolism</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Omeprazole - administration & dosage</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Omeprazole - pharmacology</topic><topic>Omeprazole - therapeutic use</topic><topic>Peptic Ulcer - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BLUM, R. A</creatorcontrib><creatorcontrib>HUNT, R. H</creatorcontrib><creatorcontrib>KIDD, S. L</creatorcontrib><creatorcontrib>SHI, H</creatorcontrib><creatorcontrib>JENNINGS, D. E</creatorcontrib><creatorcontrib>GRESKI-ROSE, P. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BLUM, R. A</au><au>HUNT, R. H</au><au>KIDD, S. L</au><au>SHI, H</au><au>JENNINGS, D. E</au><au>GRESKI-ROSE, P. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dose–response relationship of lansoprazole to gastric acid antisecretory effects</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1998-04</date><risdate>1998</risdate><volume>12</volume><issue>4</issue><spage>321</spage><epage>327</epage><pages>321-327</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Background:
Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro‐oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent upon the degree and duration of acid suppression and the length of treatment.
Objective:
To evaluate the extent and duration of gastric acid suppression of several lansoprazole regimens, administered for 5 consecutive days in 32 healthy adult male subjects.
Methods:
Intragastric 24‐h pH monitoring was performed in 32 healthy subjects in a randomized, double‐blind, four‐way crossover study. Sixteen subjects (Group 1) received lansoprazole 30 mg o.d. (once daily), 15 mg b.d. (twice daily), 30 mg b.d. and 30 mg t.d.s. (three times a day) for 5 days; and 16 subjects (Group 2) received lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. for 5 days.
Results:
Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 15 mg b.d., 30 mg b.d. and 30 mg t.d.s. were 4.47, 4.57, 5.07 and 5.63, respectively. Multiple‐dose regimens of lansoprazole 30 mg b.d. and t.d.s. produced greater acid suppression compared to lansoprazole 30 mg o.d. and 15 mg b.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 15 mg b.d. Mean 24‐h intragastric pH values for lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. were 4.13, 4.45, 5.19 and 5.13, respectively. Multiple‐dose regimens of lansoprazole 60 mg b.d. and t.d.s. produced significantly greater acid suppression compared to lansoprazole 30 mg o.d. and 60 mg o.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 60 mg o.d. Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s. produced significantly greater percentage time above pH 3, 4, 5 and 6 than did lansoprazole 30 mg o.d. Post‐regimen serum gastrin values increased by 50–130% from pre‐study mean values but remained within normal range and returned to pre‐study values 7–14 days post‐dosing.
Conclusions:
Multiple‐dose regimens of lansoprazole (≥30 mg b.d. for 5 days) produce significantly increased intragastric pH and significantly longer duration of increased intragastric pH than does lansoprazole 30 mg administered once daily.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>9690720</pmid><doi>10.1046/j.1365-2036.1998.00306.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 1998-04, Vol.12 (4), p.321-327 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80047594 |
| source | MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Administration, Oral Adult Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - pharmacology Anti-Ulcer Agents - therapeutic use Biological and medical sciences Cross-Over Studies Digestive system Dose-Response Relationship, Drug Double-Blind Method Gastric Acid - metabolism Gastroesophageal Reflux - drug therapy Humans Lansoprazole Male Medical sciences Omeprazole - administration & dosage Omeprazole - analogs & derivatives Omeprazole - pharmacology Omeprazole - therapeutic use Peptic Ulcer - drug therapy Pharmacology. Drug treatments |
| title | Dose–response relationship of lansoprazole to gastric acid antisecretory effects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T18%3A11%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dose%E2%80%93response%20relationship%20of%20lansoprazole%20to%20gastric%20acid%20antisecretory%20effects&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=BLUM,%20R.%20A&rft.date=1998-04&rft.volume=12&rft.issue=4&rft.spage=321&rft.epage=327&rft.pages=321-327&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.1998.00306.x&rft_dat=%3Cproquest_cross%3E80047594%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80047594&rft_id=info:pmid/9690720&rfr_iscdi=true |